This study will evaluate the impact of complex thoraco-abdominal aortic aneurysm repair in coagulation during the immediate postoperative period in patients undergoing omplex thoraco-abdominal aortic aneurysm repair.
Consecutive patients undergoing complex thoraco-abdominal aortic aneurysm repair in University Hospital of Larissa, after informed consent will be included.
Refuse to participate
Prior surgery within 3 months
ASA PS > 3
Known medical history of thrombophilia or functional platelet dysfunction
All patients will be treated by the same medical team in UHL according to the European Society for Vascular Surgery (ESVS) guidelines. Preoperatively patients will be treated with aspirin 100 mg once daily for at least 5 days. Postoperatively in the absence of bleeding patients will receive aspirin 100 mg and in the absence of neurological dysfunction due to spine ischemia they will receive clopidogrel 150 mg and from the next day dual antiplatelet therapy (aspirin 100 mg and clopidogrel 75 mg). If the patient was treated with anticoagulant agents this will be discontinued preoperative according to ACCP guidelines and it will be restarted on the 1st or 2nd postoperative day based on hemostasis. In this case patients will be treated with aspirin 100 mg once daily five days preoperatively and aspirin will also be continued postoperatively.
Cohort
Prospective
Patients undergoing complex thoraco-abdominal aortic aneurysm repair
Other interventionPatients undergoing complex thoraco-abdominal aortic aneurysm repair
Coagulation status
Early preoperatively, early and late postoperatively
Myocardial injury after non cardiac surgery
Early preoperatively, early and late postoperatively
Acute kidney injury
Early preoperatively, early and late postoperatively
Post-implantation syndrome
Early preoperatively, early and late postoperatively
Click on the lead sponsor to view all of their trials.
